Group items tagged

Superdrug has unveiled its new fertility test service to help women to easily access information about their own fertility and enables them to take greater control of their reproductive health. The service comprises a Superdrug online doctor consultation and personalised fertility test recommendations to help women make more informed decisions about the options available to them. Superdrug's fertility test initial consultation requires customers to fill out a quick online questionnaire. This is then reviewed by Superdrug's team of online doctors, who will work with the patients to identify which fertility tests are best suited to the individual. The new service also sees Superdrug introduce three new fertility blood tests to its portfolio, ensuring greater choice and accessibility. Dr Sara Kayat, Superdrug's medical ambassador comments, "For women that have been trying to get pregnant and not succeeding, or for those who are just curious about their fertility, easy access to blood tests may help provide answers and signpost them in the right direction."

The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS. Lipoedema is more prevalent in women and very rarely affects men. It is characterised by an abnormal, usually symmetrical, accumulation of fat in the legs, hips, buttocks, and occasionally arms. It is a separate condition to obesity and lymphoedema. The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health. The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that several different liposuction techniques are used and that they may have different safety and efficacy profiles.

Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS. The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan. Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels. Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly. The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.

The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance dispensed. Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food prices. "Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand. "A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual, potential hospital admissions, and a subsequent cost to the NHS. "This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.

A new, independent search engine has launched called Vitaminology which enables the search, discovery and comparison of vitamins and supplements to empower consumers to make more informed choices and find the right products for their personal health goals and requirements. The company has set out to reduce confusion in this market through choice and high-quality information as well as access to one-to-one consultations with accredited nutritional therapists. By offering the complete package of advice, resources and products Vitaminology helps people to lead healthier lives. Mike Murphy, who is chief nutritionist for Vitaminology, comments, "This innovative platform has a powerful comparison and filtering feature that helps to simplify the choices available for consumers so they can make better self-care decisions. This is supported by access to video consultations with nutritional therapists as well as a comprehensive library of ingredient profiles, articles clustered around health conditions and unique recipes to support wellness."

Sensodyne, the No.1 dentist recommended toothpaste brand for sensitive teeth is relaunching its Sensitivity & Gum range with an improved formula and revitalised packaging. Available in two variants - Mint and Whitening - the range's dual action formula is clinically proven to protect sensitive teeth and improve gum health. Based on a sample survey from across the GB, of those that suffer from gum conditions, 71% claim to also have sensitive teeth[1]. Figures in 2022 showed that 90% of dental practices were unable to take on new adult NHS patients[2], making it challenging for adults to get support or advice from their dentist on these concerns. This shows a clear market need for a multi-purpose product which offers dual action to for sensitive teeth and gum problems. The relaunched Sensitivity & Gum range features a new Micro Foam formula which targets and removes plaque bacteria. With twice daily brushing, the formulation reaches the areas in between the teeth and along the gumline. It also builds a protective layer over sensitive areas of the teeth for daily repair, and the mint flavour gives a soothing sensation. For consumers looking for whitening benefits, the Sensitivity & Gum Whitening formulation not only helps protect sensitive teeth but helps to remove stains for whiter looking teeth resulting in a healthy and confident smile.

When you visit a hospital, one of the last things that come to mind is worrying about legal aspects and what rights you might have - or lack. But these issues and your understanding of them are more important than ever. Knowing exactly what hospitals can legally and cannot do to you is an essential part of ensuring your protection as a patient when going in for care. In this blog post, we'll break down the legal details behind being treated at a hospital so that you can feel more confident when making healthcare decisions. Let's dive into the legal aspect of visiting a hospital, outline what hospitals can and cannot do to us, discover our rights as patients, and review any other considerations worth keeping in mind! OVERVIEW OF MEDICAL MALPRACTICE LAW AND HOW IT RELATES TO VISITING A HOSPITAL When going to a hospital, concerned patients and their families should be aware of the legal risks posed in medical malpractice cases. These potential issues can have life-altering consequences if misdiagnoses, wrong medication administration, or improper treatment occurs. Now, whether you seek damages for your injuries at Staten Island University Hospital or in a different hospital in your hometown, it is important for visitors to understand that the law has set forth regulations regarding acceptable standards of care expected by our nation's hospitals. Those regulations can include procedures of qualified professionals that protect patients from financial exploitation and physical or emotional distress caused by medical negligence. Understanding how this information applies to you will help you protect yourself legally if your rights are violated while visiting a hospital.

The Association of the British Pharmaceutical Industry (ABPI) has suspended the membership of Novo Nordisk for two years due to serious breaches of its Code of Practice. The action was taken by the ABPI Board following an investigation and appeals process conducted by the Prescription Medicines Code of Practice Authority (PMCPA) which found Novo Nordisk to be in breach of the ABPI Code of Practice, including Clause 2 which deals with actions "likely to bring discredit on, or reduce confidence in, the pharmaceutical industry". Having considered the case and requesting a further detailed audit of Novo Nordisk's compliance processes, the ABPI Board decided to suspend Novo Nordisk from ABPI membership. Susan Rienow, President-Elect, ABPI, said: "The ABPI Board has carefully considered the PMCPA's case report into Novo Nordisk and the subsequent audit of their compliance procedures. "The Board expressed significant concern about Novo Nordisk's compliance activities and the very serious issues identified. As a result, the ABPI Board have taken the decision to suspend Novo Nordisk from ABPI membership.

The new 'How to Involve and Engage Patients on Digital Health Tech Innovation' learning module has been created specifically to support the development and delivery of patient-centric technologies, at a time of critical digital transformation in the NHS. The foundation level module will be freely available at www.orcha-digitalhealthacademy.com and on the Health Education England NHS Learning Hub (learninghub.nhs.uk). No training previously exists on conducting effective patient and public involvement and engagement (PPIE), leading to wasted resource on unsuitable technologies at a time when the healthcare system simply cannot afford it. The module aims to educate innovators who are creating new technology, and the clinicians who are prescribing these solutions. Crucially, the module also provides valuable support to the 500 NHS clinicians who are on the Clinical Entrepreneur Programme. The module is an introduction to the first evidence-based framework for PPIE, launched by the University of Plymouth, the AHSN Network (the national voice of the 15 academic health science networks in England) and Boehringer Ingelheim UK & Ireland. It helps to fast-track learning for the EnACT principles described in the framework, outlining how to involve patients in product innovation and critical issues such as data privacy, intellectual property, inclusivity, reimbursement, useability, and recruitment of patients.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the new research guidance published by NHS England for the integrated care systems. The guidance is said to reflect the benefits of delivering research, for patients, staff and healthcare system performance, including the economic benefits for the NHS. Jennifer Harris, ABPI's Director of Research Policy, said: "This guidance is clear on what good research practice looks like and it's great to see it out and available for the NHS to use. "A research-active NHS delivers huge value to patients, staff and the system itself. We hope that putting this guidance into action will help Integrated Care Systems realise the huge benefits that research can offer, and help make the UK once again a destination of choice for developing the medical breakthroughs people need."

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

If you have low testosterone levels, there is a good chance you have felt some physical side effects from that. You may have heard that certain physical activity helps combat the depletion, and there is truth in this. There is a link between increasing and fine-tuning an exercise agenda and raising testosterone levels. Below, the relationship is explored in more detail. WHAT DOES TESTOSTERONE DO? There is more to the function of testosterone than just in relation to your sex drive. Of course, that is important, but it also impacts muscle building, strength, energy levels, hair growth, and red blood cells. When levels are low, there are big consequences for anybody from hair loss to weak muscles and even exhaustion too. TESTOSTERONE AND OBESITY One of the biggest things that affects testosterone is being overweight. If you are carrying a few extra pounds, it would be beneficial to try to get into some healthier habits if you want to promote an organic increase in T-levels. HOW EXERCISE PLAYS A ROLE Exercise seems to be a natural inhibitor of testosterone, especially when you focus on particular strategies and workout styles such as strength training. Levels have been shown to rise immediately after exercise for anything from fifteen minutes to an hour plus. While it is different for everyone, the link is clear.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Esperion Therapeutics' non-statin therapy "bempedoic acid" has shown modest results in reducing the risk of major cardiovascular events in statin-intolerant patients in the cholesterol lowering via bempedoic acid, an ACL-inhibiting regimen (CLEAR Outcomes) trial, revealed GlobalData, a leading data and analytics company. As a result, there is substantial room for improvement in this space as a potential approval is expected in Australia in near-term based on these results, said GlobalData. According to GlobalData's Pharmaceutical Intelligence Center, the total number of diagnosed prevalent cases of dyslipidemia in Australia is expected to increase at a compound annual growth rate of approximately 1.2% from 5.2 million in 2022 to 5.4 million in 2025. Neha Myneni, Pharma Analyst at GlobalData, comments: "Bempedoic acid joins several statin alternatives that have shown the potential to reduce cardiac illnesses. However, with not much significant improvement in the outcomes, there exists a clear room for improvement for non-statin therapies in this space." Bempedoic acid is the sixth class of cholesterol-lowering drugs (other than cholesteryl-ester transfer protein isoform (CETPi) inhibitors), that has demonstrated the potential to reduce heart attacks and strokes. Other class of therapies with similar potential currently marketed in Australia include statins, bile acid resins, niacin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab, and inclisiran).

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

If you have children, it's important to make your home kid-friendly. There are several reasons why this is important for your child's development. A kid-friendly home is a haven for your child. It's a place where they can explore and play without worrying about getting hurt. It's also a place where they can feel comfortable and secure. A kid-friendly home is also a great learning environment for your child. They can learn about new things and explore their interests in a safe and nurturing setting. Finally, a kid-friendly home is just more fun! Children are naturally curious and love to play. By making your home more inviting, you will surely enjoy watching them grow and develop. So how do you make your home more kid-friendly? Here are a few tips: Get Rid of Any and All Sharp Objects It's important to make your home safe for kids, including removing any sharp objects. This means things like knives, scissors, and other sharp tools. Even seemingly innocuous items like paper clips can harm curious little ones. So go through your house and get rid of anything that could potentially hurt a child. It's better to be safe than sorry. And if you have any doubts about whether something is safe or not, err on the side of caution and get rid of it. Better safe than sorry!

Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share. Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78. Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria." J&J also said in early December that it had dropped its pursuit of the deal.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare professional.' The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022. In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data and asked for advice from the independent Commission on Human Medicines (CHM). "The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no other effective or tolerated treatment," said MHRA. "Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective or tolerated treatment or the risks do not apply."

The Health and Social Care Secretary has announced over £175 million funding to boost genomics research in the UK. Through this funding, the government aims to create the most advanced genomic healthcare system in the world. "Patients with cancer and children born with treatable rare genetic diseases are set to benefit from earlier diagnosis and faster access to treatment, following a £175 million boost to cutting-edge genomics research announced by the Health and Social Care Secretary today (Tuesday)," said DHSC. The funding will enable research which could deliver world-leading genomic healthcare to patients, which involves the study of people's DNA. "£105 million to be funded to kickstart a world-leading research study, led by Genomics England in partnership with the NHS, to explore the effectiveness of using whole genome sequencing to find and treat rare genetic diseases in newborn babies," said DHSC. "An initial £26 million to support an innovative cancer programme, led by Genomics England in partnership with the NHS, to evaluate cutting-edge genomic sequencing technology to improve the accuracy and speed of diagnosis for cancer patients and use artificial intelligence to analyse a person's DNA, alongside other information such as routine scans.

The Department of Health of Social Care (DHSC) has re-determined that all six Madopar (Co-beneldopa) preparations meet the special container criteria as outlined in Part II Clause 10 of the Drug Tariff. "The NHS dictionary of medicines and devices (dm+d) has now been updated with special container status applied to the complete pack sizes of all Madopar preparations," said PSNC. "The special container rules apply immediately to all branded or generically written prescriptions for Madopar dispensed from December 2022 onwards." The following products will be treated as special containers for prescriptions dispensed from December 2022 onwards: